Genentech Inc.’s third-quarter profit rose 2% to...
Genentech Inc.’s third-quarter profit rose 2% to $5.3 million. Revenue advanced 83% to $245.3 million. The San Francisco biotechnology company had predicted a disappointing performance because of slower-than-expected sales of its heart drug TPA, which it has decided to stop producing until 1989.
The view from Sacramento
Sign up for the California Politics newsletter to get exclusive analysis from our reporters.
You may occasionally receive promotional content from the Los Angeles Times.
